Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect and safety of semaglutide 2.4 mg once weekly on weight management in adolescents with overweight or obesity

Next Previous
Trial Profile

Effect and safety of semaglutide 2.4 mg once weekly on weight management in adolescents with overweight or obesity

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Semaglutide (Primary)
  • Indications Obesity
  • Focus Registrational; Therapeutic Use
  • Acronyms STEP TEENS
  • Sponsors Novo A/S; Novo Nordisk

Most Recent Events

  • 24 Jun 2023 Results of post-hoc analysis assessing efficacy and safety of semaglutide 2.4 mg once weekly for weight management among adolescents with obesity, presented at the European Association for the Study of the Liver Congress 2023.
  • 17 May 2023 Results of post hoc analysis assessing the improvement in body mass index in patients treated with once-weekly subcutaneous semaglutide 2.4 mg, published in the Obesity (Silver Spring, Md.).
  • 23 Dec 2022 According to a Novo Nordisk media release, U.S. Food and Drug Administration (FDA) has approved a new indication for Wegovy (semaglutide) injection 2.4 mg, making it the first-and-only prescription anti-obesity medicine for teens with once-weekly dosing.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top